Recalibrating health technology assessment methods for cell and gene therapies

Angelis, Aris ORCID: 0000-0002-0261-4634, Naci, Huseyin and Hackshaw, Allan (2020) Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38 (12). pp. 1297-1308. ISSN 1170-7690

Text (Manuscript_Cell and gene therapies_PCE_10AUG2020_Clean 2) - Accepted Version Download (402kB)

• Author

Abstract

Recently licensed cell and gene therapies have promising but highly uncertain clinical benefits. They are entering the market at very high prices, with the latest entrants costing hundreds of thousands of dollars. The significant long-term uncertainty posed by these therapies has already complicated the use of conventional economic evaluation approaches such as cost-effectiveness and cost-utility analyses, which are widely used for assessing the value of new health interventions. Cell and gene therapies also risk jeopardising healthcare systems’ financial sustainability. As a result, there is a need to recalibrate the current health technology assessment methods used to measure and compensate their value. In this paper, we outline a set of technical adaptations and methodological refinements to address key challenges in the appraisal of cell and gene therapies’ value, including the assessment of efficiency and affordability. We also discuss the potential role of alternative financing mechanisms. Ultimately, uncertainties associated with cell and gene therapies can only be meaningfully addressed by improving the evidence base supporting their approval and adoption in healthcare systems.

Item Type:	Article
Official URL:	https://www.springer.com/journal/40273
Additional Information:	© 2020 Springer Nature Switzerland AG
Divisions:	LSE Health Health Policy
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	18 Sep 2020 09:18
Last Modified:	07 Apr 2024 04:45
URI:	http://eprints.lse.ac.uk/id/eprint/106589

Actions (login required)

View Item